Developer of antibacterial therapies focused on treating multidrug‑resistant gram‑negative infections. The company’s lead product, plazomicin (marketed as Zemdri), was approved in the U.S. for complicated urinary tract infections, placing the firm among a small group of biotech companies targeting a...
No congressional trades have been disclosed for Achaogen Inc (AKAO) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.